Pomalidomide plus Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

被引：0
|
作者：
Weisel, Katja [1 ]
Dimopoulos, Meletios A. [2 ]
Cavo, Michele [3 ]
Ocio, Enrique M. [4 ]
Palumbo, Antonio [5 ]
Corradini, Paolo [6 ]
Delforge, Michel [7 ]
Oriol, Albert [8 ]
Goldschmidt, Harmut [9 ]
Conticello, Concetta [10 ]
Vacca, Angelo [11 ]
Hansson, Markus [12 ]
Miller, Neil [13 ]
Peluso, Teresa [13 ]
Sternas, Lars [14 ]
Zaki, Mohamed H. [14 ]
Moreau, Philippe [15 ]
机构：
[1] Univ Tubingen Hosp, Tubingen, Germany
[2] Univ Athens, Sch Med, GR-11527 Athens, Greece
[3] Univ Bologna, Sch Med, Bologna, Italy
[4] Hosp Univ Salamanca IBSAL, Salamanca, Spain
[5] Univ Turin, Myeloma Unit, Div Hematol, Turin, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Hosp Leuven, Leuven, Belgium
[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[9] Univ Clin Heidelberg, Heidelberg, Germany
[10] Univ Catania, Sch Med, Catania, Italy
[11] Univ Bari, Sch Med, Bari, Italy
[12] Lund Univ, Skane Univ Hosp, Lund, Sweden
[13] Celgene Corp, Boudry, Switzerland
[14] Celgene Corp, Summit, NJ USA
[15] Univ Hosp Nantes, Nantes, France
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Dao-bin Zhou
    Li Yu
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Dena DeMarco
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Jian Hou
    International Journal of Hematology, 2015, 101 : 569 - 577
  • [22] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Zhou, Dao-bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    DeMarco, Dena
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 569 - 577
  • [23] Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
    Siegel, David S.
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Baz, Rachid
    Richardson, Paul
    Delforge, Michel
    Song, Kevin W.
    San Miguel, Jesus F.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Jagannath, Sundar
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Zaki, Mohamed
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2833 - 2838
  • [24] MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan
    Hagiwara, Shotaro
    Okamoto, Shinichiro
    Matsue, Kosei
    Iida, Shinsuke
    Sunami, Kazutaka
    Komeno, Takuya
    Suzuki, Kenshi
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Tobinai, Kensei
    Chou, Takaaki
    Kaneko, Hitomi
    Iwasaki, Hiromi
    Uemura, Chie
    Tamakoshi, Hiromi
    Zaki, Mohamed H.
    Doerr, Thomas
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    BLOOD, 2015, 126 (23)
  • [25] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [26] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
    Richardson, Paul
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    Morisse, Mony
    Anderson, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
  • [27] Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
    Meletios A. Dimopoulos
    Xavier Leleu
    Philippe Moreau
    Paul G. Richardson
    Anna Marina Liberati
    Simon J. Harrison
    H. Miles Prince
    Enrique M. Ocio
    Sylvie Assadourian
    Frank Campana
    Laure Malinge
    Dorothée Sémiond
    Helgi van de Velde
    Kwee Yong
    Leukemia, 2021, 35 : 562 - 572
  • [28] Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
    Dimopoulos, Meletios A.
    Leleu, Xavier
    Moreau, Philippe
    Richardson, Paul G.
    Liberati, Anna Marina
    Harrison, Simon J.
    Prince, H. Miles
    Ocio, Enrique M.
    Assadourian, Sylvie
    Campana, Frank
    Malinge, Laure
    Semiond, Dorothee
    van de Velde, Helgi
    Yong, Kwee
    LEUKEMIA, 2021, 35 (02) : 562 - 572
  • [29] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
    Palumbo, A.
    Dimopoulos, M. A.
    Richardson, P. G.
    Siegel, D. S.
    Cavo, M.
    Corradini, P.
    Weisel, K. C.
    Delforge, M.
    Chen, C.
    Goldschmidt, H.
    Jagannath, S.
    Lockhorst, H. M.
    Moreau, P.
    Plesner, T.
    Sternas, L.
    Peluso, T.
    Hong, K.
    Herring, J.
    Yu, X.
    Zaki, M. H.
    San Miguel, J.
    HAEMATOLOGICA, 2016, 101 : 535 - 536
  • [30] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Malinge, Laure
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
12345